Industry

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

Tensred plus®: an innovative formula to combat pre-hypertension.

MASTERing food chain microbiomes – the webinar

Key outputs and innovations of direct relevance to food and agriculture from the H2020 funded MASTER project.

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

This partnership aims to leverage Microba's advanced technology platform for measuring the human gut microbiome to discover novel biomarkers for pancreatic cancer detection. 

Ode to the people – Declaration of intent by SynBalance

10 principles summarizing SynBalance's belief about taking care of people’s health.

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® in a Phase 1b Clinical Trial in Melanoma

The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.

Microbial therapeutics market: Sacco System launches ‘Microbiome’, the suite of active ingredients and services

Marco Caspani, Executive Director of the Microbiome Division of Sacco System, explains how the company is directing his efforts and strong focus to the field of Biotherapeutics with the launch of…

Scioto Biosciences announces publication of Phase 1b study in autism

The first-in-human study double-blind, placebo controlled, 28-day crossover study of the safety and tolerability of SB-121

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top